Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome

Journal of Obstetrics and Gynaecology Research

Volumn 37, Issue 8, 2011, Pages 1084-1091

  Hsiao, Sheng Mou ^a   Chang, Ting Chen ^b   Wu, Wen Yih ^a   Chen, Chi Hau ^b   Yu, Hung Jeng ^b   Lin, Ho Hsiung ^b  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antimuscarinic; Heart rate; Overactive bladder syndrome; Urodynamic study; Voiding diary

Indexed keywords

SOLIFENACIN; TOLTERODINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEART PALPITATION; HEART RATE; HUMAN; MICTURITION; NOCTURIA; OVERACTIVE BLADDER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; URINE VOLUME; URODYNAMICS; XEROSTOMIA;

ADULT; AGED; BENZHYDRYL COMPOUNDS; CRESOLS; FEMALE; HUMANS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 80052730509     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2010.01493.x     Document Type: Article

References (33)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 37-49. (Pubitemid 36151708)
2. Stewart RB, Moore MT, May FE, Marks RG, Hale WE. Nocturia: A risk factor for falls in the elderly. J Am Geriatr Soc 1992; 40: 1217-1220.
3. Cardozo L, Lisec M, Millard R et al. Randomized, doubleblind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 1919-1924. (Pubitemid 39363090)
4. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987-1006. (Pubitemid 47537675)
5. Ohtake A, UkaiM, Hatanaka T et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004; 492: 243-250. (Pubitemid 38721378)
6. Ohtake A, Saitoh C, Yuyama H et al. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull 2007; 30: 54-58. (Pubitemid 46066319)
7. Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 2003; 42: 1243-1285. (Pubitemid 37491488)
8. Chuang YC, Thomas CA, Tyagi S, Yoshimura N, Tyagi P, Chancellor MB. Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. Int Urogynecol J 2008; 19: 1353-1357.
9. Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology 2005; 65: 238-242. (Pubitemid 40248004)
10. Chapple CR, Martinez-Garcia R, SelvaggiL et al.Acomparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur Urol 2005; 48: 464-470. (Pubitemid 41188406)
11. Chapple CR, Fianu-Jonsson A, Indig M et al. Treatment outcomes in the STAR study: A subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 2007; 52: 1195-1203.
12. Stewart WF, Van Rooyen JB, CundiffGWet al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-336. (Pubitemid 44175300)
13. Michel MC, Wetterauer U, Vogel M, de la Rosette JJ. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: A 12-week, open-label, post-marketing surveillance study. Drug Saf 2008; 31: 505-514. (Pubitemid 351693683)
14. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175: 999-1004. (Pubitemid 43200054)
15. Ronchi P, Gravina GL, Galatioto GP, Costa AM, Martella O, Vicentini C. Urodynamic parameters after solifenacin treatment in menwith overactive bladder symptoms and detrusor underactivity. Neurourol Urodynam 2009; 28: 52-57.
16. Wagg A, Malone-Lee J. Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU Int 2003; 92: 969-971. (Pubitemid 37548276)
17. Seckiner I, Yesilli C, Mungan NA, Aykanat A, Akduman B. Correlations between the ICIQ-SF score and urodynamic findings. Neurourol Urodynam 2007; 26: 492-494. (Pubitemid 47036133)
18. Sand PK. The evaluation of the incontinence female. Curr Probl Obstet Gynecol Fertil 1992; 115: 107-151.
19. Wu WY, Sheu BC, Lin HH. Comparison of 20-minute pad test versus 1-hour pad test in women with stress urinary incontinence. Urology 2006; 68: 764-768.
20. Wu WY, Sheu BC, Lin HH. Twenty-minute pad test: Comparison of infusion of 250 ml of water with strong-desire amount in the bladder in women with stress urinary incontinence. Eur J Obstet Gynecol Reprod Biol 2008; 136: 121-125.
21. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of the bladder condition (PPBC): A singleitem global measure for patients with overactive bladder. Eur Urol 2006; 49: 1079-1086. (Pubitemid 43673993)
22. Schäfer W, Abrams P, Liao L et al. Good urodynamic practices: Uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodynam 2002; 21: 261-274. (Pubitemid 34411846)
23. Colli E, Parazzini F, Olivieri L et al. Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: Findings from randomized clinical trials. Eur Urol 2007; 52: 525-530. (Pubitemid 46970873)
24. Landis JR, Kaplan S, Swift S, Versi E. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol 2004; 171: 752-756. (Pubitemid 38090474)
25. Jonas U, Rackley RR. Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur Urol 2005; 48: 464-470; Eur Urol 2006; 49: 187-188. (Pubitemid 41188406)
26. Suzuki M, Ohtake A, Yoshino T et al. Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarcted rats. Eur J Pharmacol 2005; 512: 61-66. (Pubitemid 40462364)
27. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004; 3: 46-53.
28. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor - which is the main mechanism of action? Eur Urol 2003; 43: 1-5. (Pubitemid 36134308)
29. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999; 51: 651-690.
30. Ikeda K, Kobayashi S, Suzuki M et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 97-103. (Pubitemid 34762267)
31. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-974. (Pubitemid 40695027)
32. Fox K, Borer JS, Camm AJ et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823-830. (Pubitemid 47277500)
33. Daly CA, Clemens F, Sendon JL et al. Inadequate control of heart rate in patients with stable angina: Results from the European heart survey. Postgrad Med J 2010; 86: 212-217.